

Bölüm 21

SENTETİK KANABİNOİDLER

Ejder Saylav BORA

Giriş

Doğal kannabis ($\Delta 9$ -tetrahidrokannabinol), hint keneviri bitkisinden elde edilen esrar maddesidir. Santral sinir sistemi (SSS)'ne etki eden ana psikoaktif bileşen $\Delta 9$ tetrahidrokannabinol (THC)'dır (1). Sentetik kannabinoidler (SK) ise kannabinollerin bir alt grubu olup, son yıllarda uyuşturucu maddeler içinde en çok tercih edilen psikoaktif etkili yeni maddeler içinde yerini almıştır (2). K2, spice, Bonzai, Jamaika, armageddon, black mamba, dream, mad hatter, Mr. Nice Guy gibi farklı ülkelerde farklı isimlerle bilinen SK'ler birden fazla farklı sentetik içeriğe sahip olup içeriğine her geçen gün yeni maddeler eklenmektedir (3,4). 2014 yılında European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 30 adet yeni SCs bildirirken (3) 2015 yılında EU Early Warning System SK çeşidinin 137 ye ulaştığını gözlemledi (4). Bu artan içerik bağımlılık insidansı ile birlikte kannabnoidin etkinliğini de artırmaktadır. Ve bunun sonucunda birçok ülkede sentetik kanabinoidlerin (SCs) kullanımı maruana ve benzeri keyif verici maddelere alternatif olarak hızla artış göstermiştir (5). Kullanımı yasal olmayan Türkiye'de, ulusal polis departmanı raporuna göre 1 yıl içinde (2011-2012) bu ürünle ilişkili olarak tutuklanan kişi sayısı

19 kat artış saptanmıştır (6). Bu kadar yaygın olmasının nedenleri arasında etkinliğinin çok çeşitli maddelerle güçlendirilmiş olması ve taşiflaksi etkisine karşı sürekli yeni maddelerle destekleniyor olmasının yanında ucuz olması ve internet gibi denetimden uzak satışlarıyla satılabilmesi ve başlangıçta birçok ülke de yasal olması da sayılabilir.

Artan ve sürekli değişen bir içeriğe sahip olan SK'ler çok geniş spektrumlu bir yan etki yelpazesini de beraberinde getirmektedir. Daha çok öfori, anksiyete, panik atak, halüsilasyon (7) gibi noro-psikiyatrik yan etkileriyle seyretse de günümüzde serbrovasküler sistemi etkileyerek iskemik (8) ve hemorojik serbrovasküler hastalıklara (9) ve nöbetlere (10), multisistemik olarak koma ve ölümme (11), akut böbrek hasarına (12), respiratuvar sistemi etkileyerek akut (13) ve kronik diffuz alveolar hasara (14) ve daha fazla olarak da kardiovasküler sistemi etkileyerek hipotansiyon ve bradikardiye (15), myokard enfarktüsüne (16), P-dalga dispersionu ve atrial fibrilasyona eğilime (17), uzamış QTc ve mobitz tip 2 antroventriküler bloğa (18), ventriküler fibrilasyona (19) neden olabileceğini bildiren olgu sunumları mevcuttur.

Bu konu, kannabinoidlerle akut zehirlenmenin epidemiyolojik, farmakolojik, toksik klinik belirtileri ve sentetik yönetimini tartışacaktır.

Kaynakça

Mechoulam R, Gaoni Y. A total synthesis of D1-Tetrahydeocannabinol, the active constituent of Hashish. *J Am Chem Soc.* 1965;84:3273-3275.

Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL."Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. *Am J Addict.* 2012;21:320-6.

EMCDDA – Perspectives on Drugs, Synthetic Cannabinoids in Europe, 2015 http://www.emcdda.europa.eu/attachements.cfm/att_212361_EN_EMCDAA_- POD_2013_SyntheticCannabinoids.pdf (accessed December 5, 2015).

UNODOC, Global SMART Update, Vol. 13, March 2015, <https://www.unodc.org/documents/scientific/SyntheticCannabinoids.pdf>.

Law R, Schier J, Martin C, Chang A, Wolkin A. Centers for Disease Control (CDC). Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use—United States, January–May 2015. *MMWR Morb Mortal Wkly Rep* 2015;64: 618–9.

Published June 12, 2015. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6422a5.htm>. Accessed October 19, 2015.

Turkish National Police (KOM) Department. Turkish report of antismuggling and organized crime 2013. Ankara, Turkey: KOM; 2013 2013:1–103. Available at: <http://www.kom.pol.tr/SiteAssets/Sayfalar/Raporlar/2013eng.pdf>. Accessed September 15, 2014.

Besli GE, Ikiz MA, Yildirim S, et al. Synthetic cannabinoid abuse in adolescents: a case series. *J Emerg Med.* 2015;49(5):644–650.

M. Takematsu, R. S. Hoffman, L. S. Nelson, J. M. Schechter, J. H. Moran & S. W. Wiener (2014) A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid, *Clinical Toxicology*, 52:9, 973-975, DOI: 10.3109/15563650.2014.958614

David Z. Rose, MD, Waldo R. Guerrero, MD, Maxim V. Mokin, MD, PhD, Clifton L. Gooch, MD, Andrea C. Bozeman, ARNP Julia M. Pearson, PhD, W. Scott Burgin, MD. HEMORRHAGIC STROKE FOLLOWING USE OF THE SYNTHETIC MARIJUANA "SPICE" American Academy of Neurology.

2015 Sep 29; 85(13): 1177-1179. doi: 10.1212/WNL.00000000000001973

Sampson CS1, Bedy SM2, Carlisle T2. Withdrawal seizures seen in the setting of synthetic cannabinoid abuse. *Am J Emerg Med.* 2015 Nov;33(11):1712.e3. doi: 10.1016/j.ajem.2015.03.025. Epub 2015 Mar 14.

Thornton SL1, Akpunonu P2, Glauner K2, Hoehn KS3, Gerona R4.

Unintentional Pediatric Exposure to a Synthetic Cannabinoid (AB- PINACA) Resulting in Coma and Intubation. *Ann Emerg Med.* 2015 Sep;66(3):343-4. doi: 10.1016/j.annemergmed.2015.05.021.

G. L. Buser, R. R. Gerona, B. Z. Horowitz, K. P. Vian, M. L. Troxell, R. G.

Hendrickson, D. C. Houghton, D. Rozansky, S. W. Su & R. F. Leman (2014) Acute kidney injury associated with smoking synthetic cannabinoid, *Clinical Toxicology*, 52:7, 664-673, DOI: 10.3109/15563650.2014.932365

Yamanoglu A, Cakmak S, Celebi Yamanoglu NG, et al. A new side effect of synthetic cannabinoid use by the bucket (waterpipe) method: acute respiratory distress syndrome (ARDS). *Turkish Journal of Emergency Medicine.* Volume 18, Issue 1, March 2018, Pages 42-44; <https://doi.org/10.1016/j.tjem.2017.06.001>.

Loschner A, Cihla A, Jalali F, et al. Diffuse alveolar hemorrhage: add "greenhouse effect" to the growing list. *Chest.* 2011; 140:149A. doi: 10.1378/chest.1119854. [Cross Ref]

Benowitz NL, Jones RT (1975) Cardiovascular effects of prolonged delta-9- tetrahydro-cannabinol ingestion. *Clin Pharmacol Ther* 18:287-297

Thornton SL1, Akpunonu P2, Glauner K2, Hoehn KS3, Gerona R4.

Unintentional Pediatric Exposure to a Synthetic Cannabinoid (AB- PINACA) Resulting in Coma and Intubation. *Ann Emerg Med.* 2015 Sep;66(3):343-4. doi: 10.1016/j.annemergmed.2015.05.021.

Esra Aydin Sunbul, Murat Sunbul, Ayse Terzi, Sumeyye Calli, Esra Koca, Rabia Bilici, Serhat Citak, The effect of synthetic cannabinoids on P- wave dispersion: an observational study, *Bulletin of Clinical Psychopharmacology* 2015;25(Suppl. 1): S54-S5

Von Der Haar J1, Talebi S2, Ghobadi F1, Singh S3, Chirurgi R1, Rajeswari P1, Kalantari H1, Has-sen GW1. Synthetic Cannabinoids and Their Effects on the Cardiovascular System. *J Emerg Med.* 2016 Feb;50(2):258-62. doi: 10.1016/j.jemermed.2015.10.009. Epub 2015 Oct 26. manoglu A, Celebi Yamano-

glu NG, Evran T, Sogut O. How much can synthetic cannabinoid damage the heart? A case of cardiogenic shock following resistant ventricular fibrillation after synthetic cannabinoid use. *J Clin Ultrasound*. 2018;1–5. DOI: 10.1002/jcu.22581

Understanding the Spice Phenomenon. European Monitoring Centre for Drugs and Drug Addiction. http://www.emcdda.europa.eu/attachements.cfm/att_80086_EN_Spic_e%20Thematic%20paper%20-%20final%20version.pdf (Accessed on July 01, 2014).

Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: temporary placement of four synthetic cannabinoids into Schedule I. Final order. *Fed Regist* 2014; 79:7577.

Adams AJ, Banister SD, Irizarry L, et al. "Zombie" Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York. *N Engl J Med* 2017; 376:235.

European Monitoring Centre for Drugs and Drug Addiction: Annual report on the state of the drugs problem in Europe; Lisbon, Portugal, November 2012. <https://www.emcdda.europa.eu/publications/annual-report/2012> (Accessed on July 01, 2014).

Law R, Schier J, Martin C, et al. Notes from the Field: Increase in Reported Adverse Health Effects Related to Synthetic Cannabinoid Use - United States, January-May 2015. *MMWR Morb Mortal Wkly Rep* 2015; 64:618.

Hoyte CO, Jacob J, Monte AA, et al. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in

2010. *Ann Emerg Med* 2012; 60:435.

Springer YP, Gerona R, Scheunemann E, et al. Increase in Adverse Reactions Associated with Use of Synthetic Cannabinoids - Anchorage, Alaska, 2015-2016. *MMWR Morb Mortal Wkly Rep* 2016; 65:1108.

Riederer AM, Campelman SL, Carlson RG, et al. Acute Poisonings from Synthetic Cannabinoids - 50 U.S. Toxicology Investigators Consortium Registry Sites, 2010-2015. *MMWR Morb Mortal Wkly Rep* 2016; 65:692.

Palamar JJ, Barratt MJ, Coney L, Martins SS. Synthetic Cannabinoid Use Among High School Seniors. *Pediatrics* 2017; 140.

United Nations Office on Drugs and Crime, Synthetic Cannabinoids in Herbal Products, s.11-12 (2010).

EMCDDA, Thematic Paper, Understanding the Spice Phenomenon (2009). EMCDDA, Perspectives on Drugs - Synthetic Cannabinoids in Europe, s. 3 (2015).

EMCDDA, European Database on New Drugs (EDND), <https://login.emcdda.europa.eu> (Son erişim tarihi: 25.01.2016).

Akgür S. A., Ege Üniversitesi Madde Bağımlılığı, Toksikoloji ve İlaç Bilimleri - BATI Enstitüsü, Kannabinoidlerin Toksikolojisi Sentetik Kannabinoidler ve Analitik Yaklaşımlar (2014).

Cohen J, Morrison S, Greenberg J, Saidinejad M. Clinical presentation of intoxication due to synthetic cannabinoids. *Pediatrics* 2012; 129:e1064.

Ashton JC. Synthetic cannabinoids as drugs of abuse. *Curr Drug Abuse Rev* 2012; 5:158.

Kemp AM, Clark MS, Dobbs T, et al. Top 10 Facts You Need to Know About Synthetic Cannabinoids: Not So Nice Spice. *Am J Med* 2016; 129:240.

Musselman ME, Hampton JP. "Not for human consumption": a review of emerging designer drugs. *Pharmacotherapy* 2014; 34:745.

Dresen S, Ferreira N, Pütz M, et al. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. *J Mass Spectrom* 2010; 45:1186.

Kronstrand R, Roman M, Andersson M, Eklund A. Toxicological findings of synthetic cannabinoids in recreational users. *J Anal Toxicol* 2013; 37:534.

Seywright A, Torrance HJ, Wylie FM, et al. Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA. *Clin Toxicol (Phila)* 2016; 54:632.

Mir A, Obafemi A, Young A, Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. *Pediatrics* 2011; 128:e1622.

Buser GL, Gerona RR, Horowitz BZ, et al. Acute kidney injury associated with smoking synthetic cannabinoid. *Clin Toxicol (Phila)* 2014; 52:664.

Arntson A, Ofsa B, Lancaster D, et al. Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens. *J Anal Toxicol* 2013; 37:284.

Freijo TD Jr, Harris SE, Kala SV. A rapid quantitative method for the analysis of synthetic cannabinoids by liquid chromatography-tandem mass spectrometry. *J Anal Toxicol* 2014; 38:466.

Rose DZ, Guerrero WR, Mokin MV, et al. Hemorrhagic stroke following use of the synthetic marijuana "spice". *Neurology* 2015; 85:1177.

Sağlık Bilimleri Dahili Bilimler

Freeman MJ, Rose DZ, Myers MA, et al. Ischemic stroke after use of the synthetic marijuana "spice". Neurology 2013; 81:2090.

Bhanushali GK, Jain G, Fatima H, et al. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol 2013; 8:523.

Outbreak alert: Potential life-threatening vitamin K-dependent antagonist coagulopathy associated with synthetic cannabinoids use. Centers for Disease Control and Prevention. April 5, 2018. <https://content.govdelivery.com/accounts/USCDC/bulletins/1e6dac3>.

Moritz E, Austin C, Wahl M, et al. Notes from the Field: Outbreak of Severe Illness Linked to the Vitamin K Antagonist Brodifacoum and Use of Synthetic Cannabinoids - Illinois, March-April 2018. MMWR Morb Mortal Wkly Rep 2018; 67:607.